Blueprint Medicines Corp (NASDAQ: BPMC) is -4.31% lower on its value in year-to-date trading and has touched a low of $41.54 and a high of $101.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BPMC stock was last observed hovering at around $87.97 in the last trading session, with the day’s gains setting it 0.29%.
Currently trading at $88.26, the stock is -2.99% and 3.82% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.28 million and changing 0.33% at the moment leaves the stock 33.05% off its SMA200. BPMC registered 94.79% gain for a year compared to 6-month gain of 71.95%. The firm has a 50-day simple moving average (SMA 50) of $20.15 and a 200-day simple moving average (SMA200) of -$10.69.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -3.28% loss in the last 1 month and extending the period to 3 months gives it a 0.74%, and is -2.58% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.47% over the week and 5.24% over the month.
Blueprint Medicines Corp (BPMC) has around 655 employees, a market worth around $5.40B and $249.38M in sales. Profit margin for the company is -203.30%. Distance from 52-week low is 112.47% and -12.61% from its 52-week high. The company has generated returns on investments over the last 12 months (-61.58%).
Blueprint Medicines Corp quarterly earnings per share for the current quarter are estimated at -$1.66 with sales reaching $80.34M over the same period.The EPS is expected to grow by 33.10% this year, but quarterly earnings will post 57.50% year-over-year. Quarterly sales are estimated to grow 26.90% in year-over-year returns.
370 institutions hold shares in Blueprint Medicines Corp (BPMC), with institutional investors hold 107.34% of the company’s shares. The shares outstanding are 61.15M, and float is at 59.79M with Short Float at 8.59%. Institutions hold 106.37% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 6.71 million shares valued at $423.95 million. The investor’s holdings represent 11.06% of the BPMC Shares outstanding. As of Jun 29, 2023, the second largest holder is Blackrock Inc. with 6.54 million shares valued at $413.06 million to account for 10.77% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 5.93 million shares representing 9.77% and valued at over $374.74 million, while Price (T.Rowe) Associates Inc holds 9.27% of the shares totaling 5.62 million with a market value of $355.4 million.
Blueprint Medicines Corp (BPMC) Insider Activity
The most recent transaction is an insider sale by Landsittel Michael, the company’s CHIEF FINANCIAL OFFICER. SEC filings show that Landsittel Michael sold 13,734 shares of the company’s common stock on Mar 15 ’24 at a price of $87.78 per share for a total of $1.21 million. Following the sale, the insider now owns 47286.0 shares.
Blueprint Medicines Corp disclosed in a document filed with the SEC on Mar 15 ’24 that Hurley Ariel (PRINCIPAL ACCOUNTING OFFICER) sold a total of 4,549 shares of the company’s common stock. The trade occurred on Mar 15 ’24 and was made at $87.76 per share for $0.4 million. Following the transaction, the insider now directly holds 14913.0 shares of the BPMC stock.
Still, SEC filings show that on Mar 13 ’24, Lee Philina (CHIEF COMMERCIAL OFFICER) disposed off 8,023 shares at an average price of $90.40 for $0.73 million. The insider now directly holds 34,729 shares of Blueprint Medicines Corp (BPMC).
